Unlike many cancer vaccines designed to elicit potent CTL responses, CIMAvax-EGF intends to starve cancer cells overexpressing epidermal growth factor receptor (EGFR) through the generation of neutralizing antibodies against its cognate ligand, EGF [125]. This evidence concerns the gene EGFR and cancer.